{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Horakova O"],"funding":["European Commission FP7"],"pagination":["e43764"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3432031"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(8)"],"pubmed_abstract":["Insulin resistance, the key defect in type 2 diabetes (T2D), is associated with a low capacity to adapt fuel oxidation to fuel availability, i.e., metabolic inflexibility. This, in turn, contributes to a further damage of insulin signaling. Effectiveness of T2D treatment depends in large part on the improvement of insulin sensitivity and metabolic adaptability of the muscle, the main site of whole-body glucose utilization. We have shown previously in mice fed an obesogenic high-fat diet that a combined use of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and thiazolidinediones (TZDs), anti-diabetic drugs, preserved metabolic health and synergistically improved muscle insulin sensitivity. We investigated here whether n-3 LC-PUFA could elicit additive beneficial effects on metabol"],"journal":["PloS one"],"pubmed_title":["Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice."],"pmcid":["PMC3432031"],"funding_grant_id":["FP7_244995"],"pubmed_authors":["Bardova K","Kopecky J","Hensler M","Rossmeisl M","Kus V","Medrikova D","Kuda O","Keijer J","Illig T","Horakova O","Adamski J","Prehn C","Bunschoten A","Janovska P","Wang-Sattler R","Flachs P","van Schothorst EM"],"additional_accession":[]},"is_claimable":false,"name":"Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice.","description":"Insulin resistance, the key defect in type 2 diabetes (T2D), is associated with a low capacity to adapt fuel oxidation to fuel availability, i.e., metabolic inflexibility. This, in turn, contributes to a further damage of insulin signaling. Effectiveness of T2D treatment depends in large part on the improvement of insulin sensitivity and metabolic adaptability of the muscle, the main site of whole-body glucose utilization. We have shown previously in mice fed an obesogenic high-fat diet that a combined use of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and thiazolidinediones (TZDs), anti-diabetic drugs, preserved metabolic health and synergistically improved muscle insulin sensitivity. We investigated here whether n-3 LC-PUFA could elicit additive beneficial effects on metabol","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012","modification":"2026-05-04T07:29:13.52Z","creation":"2019-03-26T23:11:15Z"},"accession":"S-EPMC3432031","cross_references":{"pubmed":["22952760"],"doi":["10.1371/journal.pone.0043764"]}}